Orthofix Medical Inc. operates as a spine and orthopedics company in the United States, Italy, Germany, the United Kingdom, France, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures and distributes bone growth stimulator devices for enhance of bone fusion, including adjunctive and noninvasive treatment of cervical and lumbar spine, as well as a therapeutic treatment for non-spine; designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and offers biological products, such as fiber-based and particulate demineralized bone matrices, cellular bone allografts, collagen ceramic matrices, and synthetic bone void fillers, and tissue forms, which allow physicians to treat various spinal and orthopedic conditions. This segment also designs, develops, and markets a portfolio of navigation technologies, including tracked surgical tools, intelligent software, and imaging equipment based on machine-vision and optical innovations. The Global Orthopedics segment offers products and solutions that allow physicians to treat various orthopedic conditions related to limb reconstruction and deformity correction unrelated to the spine. This segment designs, develops, and markets external and internal fixation orthopedic products that are coupled with enabling digital technologies to serve the complete patient treatment pathway. It sells its products through distributors and sales representatives to hospitals, healthcare organizations, and healthcare providers. The company was formerly known as Orthofix International N.V. and changed its name to Orthofix Medical Inc. in 2018. Orthofix Medical Inc. was founded in 1980 and is headquartered in Lewisville, Texas.

Orthofix Medical Inc.

Intuitive Surgical, Inc. (ISRG) came out with quarterly earnings of $1.81 per share, beating the Zacks Consensus Estimate of $1.71 per share. This compares to earnings of $1.50 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of 5.85%. A quarter ago, it was expected that this company would post earnings of $1.77 per share when it actually produced earnings of $2.21, delivering a surprise of 24.86%.
Over the last four quarters, the company has surpassed consensus EPS estimates four times.
Intuitive Surgical, which belongs to the Zacks Medical - Instruments industry, posted revenues of $2.25 billion for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 3.27%. This compares to year-ago revenues of $1.89 billion. The company has topped consensus revenue estimates three times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
Intuitive Surgical shares have lost about 10.3% since the beginning of the year versus the S&P 500's decline of -12.3%.
What's Next for Intuitive Surgical?
While Intuitive Surgical has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Intuitive Surgical: mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is $1.96 on $2.33 billion in revenues for the coming quarter and $7.97 on $9.56 billion in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Instruments is currently in the top 30% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
Another stock from the same industry, Orthofix (OFIX), has yet to report results for the quarter ended March 2025. The results are expected to be released on May 6.
This medical device maker is expected to post quarterly loss of $0.17 per share in its upcoming report, which represents a year-over-year change of +63%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.
Orthofix's revenues are expected to be $190.1 million, up 0.8% from the year-ago quarter.
Should You Invest in Intuitive Surgical, Inc. (ISRG)?
Before you invest in Intuitive Surgical, Inc. (ISRG), want to know the best stocks to buy for the next 30 days? Check out Zacks Investment Research for our free report on the 7 best stocks to buy.
Zacks Investment Research has been committed to providing investors with tools and independent research since 1978. For more than a quarter century, the Zacks Rank stock-rating system has more than doubled the S&P 500 with an average gain of +24.08% per year. (These returns cover a period from January 1, 1988 through May 6, 2024.)
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Intuitive Surgical, Inc. (ISRG) : Free Stock Analysis Report
ORTHOFIX MEDICAL INC. (OFIX) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Intuitive Surgical, Inc. (ISRG) Q1 Earnings and Revenues Beat Estimates

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares U.S. Medical Devices ETF (Symbol: IHI), we found that the implied analyst target price for the ETF based upon its underlying holdings is $69.96 per unit.
With IHI trading at a recent price near $63.81 per unit, that means that analysts see 9.64% upside for this ETF looking through to the average analyst targets of the underlying holdings. Three of IHI's underlying holdings with notable upside to their analyst target prices are Orthofix Medical Inc (Symbol: OFIX), AtriCure Inc (Symbol: ATRC), and GE HealthCare Technologies Inc (Symbol: GEHC). Although OFIX has traded at a recent price of $18.33/share, the average analyst target is 32.57% higher at $24.30/share. Similarly, ATRC has 16.21% upside from the recent share price of $39.87 if the average analyst target price of $46.33/share is reached, and analysts on average are expecting GEHC to reach a target price of $97.33/share, which is 10.23% above the recent price of $88.30. Below is a twelve month price history chart comparing the stock performance of OFIX, ATRC, and GEHC:
Below is a summary table of the current analyst target prices discussed above:
Name
Symbol
Recent Price
Avg. Analyst 12-Mo. Target
% Upside to Target
iShares U.S. Medical Devices ETF
IHI
$63.81
$69.96
9.64%
Orthofix Medical Inc
OFIX
$18.33
$24.30
32.57%
AtriCure Inc
ATRC
$39.87
$46.33
16.21%
GE HealthCare Technologies Inc
GEHC
$88.30
$97.33
10.23%
Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Do the analysts have a valid justification for their targets, or are they behind the curve on recent company and industry developments? A high price target relative to a stock's trading price can reflect optimism about the future, but can also be a precursor to target price downgrades if the targets were a relic of the past. These are questions that require further investor research.
10 ETFs With Most Upside To Analyst Targets »
Also see:
Institutional Holders of CRNT
Institutional Holders of IHDG
THRY Stock Predictions
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Analysts Predict 10% Gains Ahead For IHI

Orthofix Medical Inc. OFIX recently announced the receipt of FDA 510(k) clearance and the first U.S. implant of the Fitbone Transport and Lengthening System. The system is used to treat large bone defects in the femur and tibia due to trauma or infectious or malignant conditions. The device is the only intramedullary nail intended to extend or transfer bone in a single surgical procedure.
For treatments involving limb restoration and deformity repair, Orthofix Medical is the only orthopedic company that provides a full range of internal and exterior fixation options. The Fitbone Transport and Lengthening System is currently available in the United States under a limited market release.
More on the News
Patients with femur and tibia abnormalities are frequently difficult to treat and have had several procedures in the past. With the revolutionary new Fitbone Transport and Lengthening System, extremely difficult conditions can be fixed without the need for numerous follow-up procedures by allowing bone to be transferred across the defect.
The Fitbone Transport and Lengthening System utilizes the same motorized technology as the Fitbone TAA Intramedullary Lengthening System, a clinically proven device with more than 20 years of use and multiple publications to back it. The motorized intramedullary nail, a receiver, and an external control set make up the device, which is implanted in a minimally invasive surgery and allows the patient to manage the distraction phase at home. The receiver and nail are taken out after the course of treatment is completed.
More on Fitbone TAA Intramedullary Lengthening System
The Fitbone TAA Intramedullary Lengthening System is intended for limb lengthening of the femur and tibia. With the combination of preoperative planning, specialist Fitbone instrumentation and the Fitbone lengthening nail, it is possible to make axial and torsional corrections as part of limb lengthening.
The Fitbone Intramedullary Limb-lengthening System has been incorporated into the OrthoNext digital platform. The OrthoNext software features the reverse planning method module that simulates the target position, osteotomy level and blocking screw placement, enabling a more accurate preoperative assessment and optimized limb correction.
Industry Prospects
Per a report by Coherent Market Insights, the global orthopedic extension devices market was valued at $937.2 million in 2023 and is expected to witness a growth rate of 4% from 2023 to 2030.
Given the market potential, Orthofix Medical is likely to generate additional revenues from the sale of its Fitbone Transport and Lengthening Systempost-FDA clearance.
Notable Development
In May, Orthofix announced the receipt of FDA 510(k) clearance to market its Rodeo Telescopic Nail. The nail implant is likely to stabilize the patient’s limb while also elongating (or telescoping) to accommodate the natural growth of pediatric patients.
Price Performance
In the past six months, OFIX’s shares have gained 4.2% compared with the industry’s rise of 1.9%. The S&P 500 increased 17.3% in the same time frame.
Image Source: Zacks Investment Research
Zacks Rank & Stocks to Consider
OFIX carries a Zacks Rank #3 (Hold) at present.
Some better-ranked stocks in the broader medical space that have announced quarterly results are DaVita DVA, Ecolab ECL and Universal Health Services UHS.
DaVita, carrying a Zacks Rank of 2 (Buy) at present, has an estimated long-term growth rate of 13.6%. DVA’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 29.4%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
DaVita’s shares have gained 44% compared with the industry’s 20.4% growth in the past year.
Ecolab, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 13.3%. ECL’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 1.7%.
Ecolab’s shares have gained 33.8% against the industry’s 9.3% decline in the past year.
Universal Health Services has an Earnings ESP of +2.91% and a Zacks Rank of 2, at present. UHS has an estimated earnings growth rate of 30.5% for 2024.
UHS’ earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 8.12%.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Ecolab Inc. (ECL) : Free Stock Analysis Report
Universal Health Services, Inc. (UHS) : Free Stock Analysis Report
DaVita Inc. (DVA) : Free Stock Analysis Report
ORTHOFIX MEDICAL INC. (OFIX) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Orthofix Medical's (OFIX) Fitbone System Gets FDA Clearance

(RTTNews) - Orthofix Medical Inc. (OFIX) announced preliminary fourth quarter net sales of approximately $200.3 million, an increase of 63.8% on a reported basis and 62.8% on a constant currency basis from fourth quarter 2022. For the full year 2023, preliminary net sales were approximately $746.5 million, an increase of 62.0% on a reported basis and 61.5% on a constant currency basis.
Catherine Burzik, Chair of the Board and former Interim CEO of Orthofix, said: "Our preliminary revenue numbers reflect heightened performance and increased momentum across all business segments."
Orthofix and SeaSpine merged in January 2023 to form a global spine and orthopedics company.
For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Orthofix Medical Preliminary Q4 Net Sales Up 63.8% - Quick Facts

Shares of Orthofix Medical OFIX have plunged 4.5% since the release of its third-quarter earnings on Nov 8.
The company delivered third-quarter 2023 adjusted earnings per share (EPS) of 7 cents, down 76.7% from a year ago. However, the figure beat the Zacks Consensus Estimate of a loss of 75 cents.
The one-time adjustments include expenses associated with long-term income tax rate adjustment, strategic investments and the amortization of acquired intangibles, and medical device regulation charges, among others.
For the third quarter, GAAP loss per share was 77 cents compared with a loss of 53 cents in the year-ago period.
Total Revenues
Quarterly revenues totaled $184 million, up 61.4% year over year on a reported basis and 8% at Constant Exchange Rate (CER). Yet, the metric missed the Zacks Consensus Estimate by a marginal 0.8%.
Segmental Details
Across product categories, Bone Growth Therapies’ revenues reached $53.4 million, up 14.7% year over year and at CER. The rise was driven by growth in both spine and fracture portfolios.
Revenues from Spinal Implants, Biologics and Enabling Technologies were $101 million, up 154.7% year over year (154.5% at CER).
The Global Spine business' revenues increased 79.1% year over year to $154.4 million.
The Global Orthopedics business' revenues climbed 6.6% year over year (up 0.7% at CER) to $29.7 million.
Margins
In the reported quarter, gross profit rose 43.6% year over year to $119.8 million. The gross margin contracted 809 basis points to 65.1%.
Sales and marketing, general and administrative, and research and development expenses escalated 71.2%, 40.4% and 55.4% year over year to $94.9 million, $27.1 million and $18.6 million, respectively.
ORTHOFIX MEDICAL INC. Price, Consensus and EPS Surprise
Adjusted operating loss for the quarter was $20.9 million compared with $3.3 million in the prior-year period.
Operational Update
The company exited third-quarter 2023 with cash and cash equivalents of $33.6 million compared with $38 million at the end of second-quarter 2023.
Cumulative net cash used in operating activities at the end of third quarter was $39.1 million against the prior-year period’s cash flow of $13.9 million.
Cumulative capital expenditure incurred by OFIX at third-quarter end was $46.9 million compared with $17.3 million at second-quarter end.
Accordingly, cumulative free cash flow at the end of third quarter was ($86.1) million. It reported free cash outflow of $31.1 million at the prior-year end.
2023 Outlook
Orthofix updated its guidance for 2023. The guidance is based on current foreign-currency exchange rates and do not take into account any additional potential exchange rate changes that may occur this year.
For 2023, management expects net sales in the $739-$744 million band (previous guided range was $752-$758 million).The Zacks Consensus Estimate is pegged at $742.2 million.
Our Take
Orthofix exited the third quarter of 2023 with better-than-expected earnings, while revenues lagged estimates. It registered year-over-year revenue growth on the back of strength in global spine business.
During the quarter, it witnessed very strong growth across multiple business segments and product lines. Orthofix’s complementary portfolio is driving even further incremental cross-selling opportunities.
However, a contraction in both margins does not bode well. The increase in sales and marketing expense is primarily driven by integration-related severance, retention costs, stock-based compensation associated with the merger and higher commissions as a result of the achievement of certain sales objectives. The company lowered its 2023 sales outlook, raising apprehension.
Zacks Rank
Orthofix currently has a Zacks Rank #2 (Buy).
Other Key Picks
Some other top-ranked stocks in the broader medical space are Haemonetics HAE,Insulet PODD and DexCom DXCM. While Haemonetics and DexCom currently carry a Zacks Rank #2 each, Insulet sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Haemonetics’ stock has risen 11.6% in the past year. Estimates for Haemonetics’ 2023 and 2024 EPS have increased from $3.82 to $3.86 and $4.07 to $4.11, respectively, in the past 30 days.
HAE’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 16.1%. In the last reported quarter, it posted earnings surprise of 5.3%.
Estimates for Insulet’s 2023 EPS have jumped from $1.61 to $1.90 in the past 30 days. The stock has fallen 40.9% in the past year compared with the industry’s decline of 7%.
PODD’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 105.1%. In the last reported quarter, it delivered earnings surprise of 77.4%.
Estimates for DexCom’s 2023 EPS have ascended from $1.23 to $1.41 in the past 30 days. Shares of DXCM have dipped 7.8% in the past year compared with the industry’s decline of 7.1%.
DXCM’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 36.4%. In the last reported quarter, it reported earnings surprise of 47.1%.
7 Best Stocks for the Next 30 Days
Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."
Since 1988, the full list has beaten the market more than 2X over with an average gain of +24.0% per year. So be sure to give these hand-picked 7 your immediate attention.
See them now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Orthofix (OFIX) Q3 Earnings Top Estimates, 2023 Sales View Cut

The NASDAQ 100 After Hours Indicator is up 1.25 to 16,028.31. The total After hours volume is currently 94,257,629 shares traded.
The following are the most active stocks for the after hours session:
Arcutis Biotherapeutics, Inc. (ARQT) is unchanged at $2.07, with 4,286,682 shares traded. ARQT's current last sale is 23% of the target price of $9.
Newmont Corporation (NEM) is unchanged at $36.56, with 2,837,421 shares traded. As reported by Zacks, the current mean recommendation for NEM is in the "buy range".
Orthofix Medical Inc. (OFIX) is -0.0012 at $10.82, with 2,816,716 shares traded. OFIX's current last sale is 52.77% of the target price of $20.5.
Ford Motor Company (F) is unchanged at $10.34, with 2,798,714 shares traded. F's current last sale is 73.86% of the target price of $14.
Sea Limited (SE) is -0.0194 at $38.50, with 2,697,779 shares traded. As reported by Zacks, the current mean recommendation for SE is in the "buy range".
Palantir Technologies Inc. (PLTR) is -0.03 at $21.31, with 2,557,152 shares traded. Over the last four weeks they have had 3 up revisions for the earnings forecast, for the fiscal quarter ending Sep 2024. The consensus EPS forecast is $0.04. , following a 52-week high recorded in today's regular session.
PDD Holdings Inc. (PDD) is unchanged at $118.78, with 2,483,265 shares traded.PDD is scheduled to provide an earnings report on 11/27/2023, for the fiscal quarter ending Sep2023. The consensus earnings per share forecast is 0.99 per share, which represents a 103 percent increase over the EPS one Year Ago
Alphabet Inc. (GOOGL) is +0.09 at $136.34, with 2,224,528 shares traded. Over the last four weeks they have had 3 up revisions for the earnings forecast, for the fiscal quarter ending Dec 2023. The consensus EPS forecast is $1.6. As reported by Zacks, the current mean recommendation for GOOGL is in the "buy range".
Zoom Video Communications, Inc. (ZM) is +0.94 at $66.94, with 2,208,199 shares traded. As reported in the last short interest update the days to cover for ZM is 7.144845; this calculation is based on the average trading volume of the stock.
KeyCorp (KEY) is unchanged at $12.25, with 2,196,924 shares traded. Over the last four weeks they have had 4 up revisions for the earnings forecast, for the fiscal quarter ending Mar 2024. The consensus EPS forecast is $0.26. KEY's current last sale is 94.23% of the target price of $13.
Advanced Micro Devices, Inc. (AMD) is +0.1 at $121.63, with 2,111,482 shares traded. Over the last four weeks they have had 3 up revisions for the earnings forecast, for the fiscal quarter ending Sep 2024. The consensus EPS forecast is $0.81. As reported by Zacks, the current mean recommendation for AMD is in the "buy range".
Walt Disney Company (The) (DIS) is -0.07 at $94.96, with 2,098,014 shares traded. As reported by Zacks, the current mean recommendation for DIS is in the "buy range".
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

After Hours Most Active for Nov 20, 2023 : ARQT, NEM, OFIX, F, SE, PLTR, PDD, GOOGL, ZM, KEY, AMD, DIS

(RTTNews) - Orthofix Medical Inc. (OFIX) announced the full U.S. commercial launch of the WaveForm L Lateral Lumbar Interbody System. The 3D-printed WaveForm L features a porous structure that prioritizes strength and stability to provide a robust fusion environment.
Kevin Kenny, President of Orthofix Global Spine, said: "WaveForm L represents the latest advancements in proprietary spinal implant technology engineered to address the many nuances of spinal pathology to meet individual patient needs, delivering both clinical and economic value to patients, surgeons and hospital systems."
The company noted that, according to 2022 data, the Lateral lumbar interbody fusion market is estimated to be more than $350 million in the U.S.
For More Such Health News, visit rttnews.com.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Orthofix Medical Announces Launch Of WaveForm L Lateral Lumbar Interbody System - Quick Facts

Fintel reports that on October 20, 2023, Roth MKM initiated coverage of Orthofix Medical (NASDAQ:OFIX) with a Neutral recommendation.
Analyst Price Forecast Suggests 126.62% Upside
As of October 5, 2023, the average one-year price target for Orthofix Medical is 26.26. The forecasts range from a low of 16.16 to a high of $37.28. The average price target represents an increase of 126.62% from its latest reported closing price of 11.59.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Orthofix Medical is 490MM, a decrease of 18.05%. The projected annual non-GAAP EPS is 0.80.
What is the Fund Sentiment?
There are 397 funds or institutions reporting positions in Orthofix Medical. This is a decrease of 40 owner(s) or 9.15% in the last quarter. Average portfolio weight of all funds dedicated to OFIX is 0.10%, an increase of 6.71%. Total shares owned by institutions increased in the last three months by 1.54% to 37,656K shares. The put/call ratio of OFIX is 0.25, indicating a bullish outlook.
What are Other Shareholders Doing?
First Light Asset Management holds 2,459K shares representing 6.69% ownership of the company. In it's prior filing, the firm reported owning 2,651K shares, representing a decrease of 7.80%. The firm decreased its portfolio allocation in OFIX by 12.94% over the last quarter.
IJR - iShares Core S&P Small-Cap ETF holds 2,447K shares representing 6.66% ownership of the company. In it's prior filing, the firm reported owning 2,488K shares, representing a decrease of 1.66%. The firm increased its portfolio allocation in OFIX by 2.72% over the last quarter.
Armistice Capital holds 2,436K shares representing 6.63% ownership of the company. In it's prior filing, the firm reported owning 1,836K shares, representing an increase of 24.63%. The firm increased its portfolio allocation in OFIX by 43.75% over the last quarter.
Rubric Capital Management holds 2,392K shares representing 6.51% ownership of the company. In it's prior filing, the firm reported owning 2,044K shares, representing an increase of 14.58%. The firm increased its portfolio allocation in OFIX by 108.16% over the last quarter.
Segall Bryant & Hamill holds 2,066K shares representing 5.62% ownership of the company. In it's prior filing, the firm reported owning 2,086K shares, representing a decrease of 0.98%. The firm increased its portfolio allocation in OFIX by 3.59% over the last quarter.
Orthofix Medical Background Information
(This description is provided by the company.)
Orthofix Medical Inc. is a global medical device and biologics company with a spine and extremities focus. The Company's mission is to deliver innovative, quality-driven solutions as it partners with health care professionals to improve patients' lives. Headquartered in Lewisville, Texas, Orthofix's spine and orthopedic extremities products are distributed in more than 70 countries via the Company's sales representatives and distributors.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Roth MKM Initiates Coverage of Orthofix Medical (OFIX) with Neutral Recommendation

Orthofix Medical Inc. OFIX recently gained FDA 510k clearance for its advanced bioactive synthetic graft, OsteoCove. Following the approval, the company announced the full commercial launch of the same.
The latest development significantly strengthens Orthofix’s biologics portfolio of the Global Spine segment and builds on its mission to deliver best-in-class products to every major bone-grafting category.
More on OsteoCove
The company recognizes OsteoCove as a prime example of leveraging its strengths in product development in combination with its vertically integrated manufacturing expertise. Available in both a putty and strip configuration, OsteoCove was carefully formulated to provide superior bone-forming capabilities with best-in-class handling characteristics for a wide range of spine and orthopedic procedural applications.
Image Source: Zacks Investment Research
The product is made of biphasic ceramic granules comprised of β-tricalcium phosphate and hydroxyapatite combined with type-I bovine collagen. OsteoCove features a specialized granule surface topography designed to elicit a bone-forming response, as demonstrated by its ability to grow bones in a challenging muscle pouch model. This specialized surface chemistry and microporosity are shown to promote superior bone formation compared to other commercially available advanced synthetic grafts.
News in Detail
Orthofix’s spokesperson said that they have used the same disciplined R&D approach in creating the OsteoCove graft, which they have historically taken with respect to the internally processed demineralized bone matrix solutions. The company continues to deliver on its commitment to provide surgeons with a comprehensive offering of biologic solutions to meet their patients’ needs.
OsteoCove’s introduction is expected to generate strong growth in the large synthetic bone graft market segment, which challenges the performance expectations of typical synthetic bone graft substitutes.
Industry Prospects
Per a research report, the global bone graft and substitute market was valued at $2.80 billion in 2022 and is expected to witness a CAGR of 6.3% by 2030.
Other Highlights Within the Global Spine Segment
In August 2023, OFIX announced the full commercial launch and successful completion of the first cases in the United States with the 7D FLASH Navigation System Percutaneous Module 2.0. The launch expands the clinical functionality and utility of the 7D FLASH Navigation System by providing surgeons with a fully integrated procedural solution for Minimally Invasive Surgery, including implant planning and an expanded offering of navigated tools.
In June 2023, Orthofix made the full commercial availability of the WaveForm A interbody for Anterior Lumbar Interbody Fusion procedures. The system integrates the most advanced technologies into the company’s surgical sets, minimizing the need for multiple instrument sets during the procedure.
Over the past year, Orthofix shares have decreased 18.3% compared with the industry’s decline of 1.9%.
Zacks Rank and Key Picks
Orthofix currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space are Cardinal Health CAH, Haemonetics HAE and Align Technology ALGN, each carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Cardinal Health stock has risen 31.1% in the past year. Earnings estimates for the company have increased from $6.65 to $6.66 in 2023 in the past 30 days and from $7.56 to $7.57 for 2024 in the past seven days.
CAH’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 16.03%. In the last reported quarter, it posted an earnings surprise of 4.73%.
Estimates for Haemonetics’ 2023 earnings per share have remained constant at $3.82 in the past 30 days. Shares of the company have increased 13.1% in the past year against the industry’s decline of 10.3%.
HAE’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 19.39%. In the last reported quarter, it posted an earnings surprise of 38.16%.
Estimates for Align Technology’s 2023 earnings have moved up from $8.77 to $8.78 per share in the past 30 days. Shares of the company have increased 29.7% in the past year compared with the industry’s growth of 19.1%.
ALGN’s earnings beat estimates in three of the trailing four quarters and missed in one. In the last reported quarter, it posted an earnings surprise of 9.90%.
Infrastructure Stock Boom to Sweep America
A massive push to rebuild the crumbling U.S. infrastructure will soon be underway. It’s bipartisan, urgent, and inevitable. Trillions will be spent. Fortunes will be made.
The only question is “Will you get into the right stocks early when their growth potential is greatest?”
Zacks has released a Special Report to help you do just that, and today it’s free. Discover 5 special companies that look to gain the most from construction and repair to roads, bridges, and buildings, plus cargo hauling and energy transformation on an almost unimaginable scale.
Download FREE: How To Profit From Trillions On Spending For Infrastructure >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.